Information on Federal Contributions to Remdesivir (GAO-21-272)
Summary
A GAO report to congressional addressees, GAO-21-272, dated March 2021, on federal contributions to remdesivir, an antiviral drug patented and manufactured by Gilead Sciences, Inc. It reports that between 2013 and 2020 the Centers for Disease Control and Prevention, the Department of Defense and the National Institutes of Health conducted and funded preclinical research collaborations with Gilead that helped to demonstrate remdesivir's antiviral properties against multiple viruses. NIH also funded three clinical trials. GAO states that between 2009 and 2013 Gilead had synthesized the compound.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Full text
United States Government Accountability Office
Report to Congressional Addressees
BIOMEDICAL
March 2021
RESEARCH
Information on
Federal Contributions
to Remdesivir
GAO-21-272
March 2021
BIOMEDICAL RESEARCH
Information on Federal Contributions to Remdesivir
Highlights of GAO-21-272, a report to
congressional addressees
Why GAO Did This Study What GAO Found
Remdesivir is an antiviral drug Between 2013 and 2020, the Centers for Disease Control and Prevention (CDC),
patented and manufactured by Gilead. the Department of Defense (DOD), and the National Institutes of Health (NIH)
Along with its parent compound, conducted and funded preclinical research collaborations with Gilead Sciences,
remdesivir was originally developed to Inc. (Gilead) that helped to demonstrate remdesivir’s antiviral properties against
treat viral hepatitis and a viral multiple viruses. NIH also funded three clinical trials. (See figure for examples of
respiratory infection. Remdesivir was federal support.) Between 2009 and 2013, Gilead had synthesized the remdesivir
later studied for antiviral activity compound, conducted and funded preclinical research that first identified and
against multiple viruses. It was the first confirmed the antiviral activity of remdesivir and its parent compound against
drug approved by the FDA to treat
coronaviruses and other viruses, and had begun patenting the compounds. As of
COVID-19. Public interest
December 2020, federal funding for preclinical studies and clinical trials involving
organizations have raised questions
about the extent of federal support for
remdesivir totaled about $162 million, as follows:
the development of remdesivir. • $0.7 million for CDC’s preclinical research;
Federal support can benefit the public • $39.7 million for DOD’s preclinical research;
by creating new inventions and may • $11.9 million for preclinical research conducted by NIH and NIH-funded
result in certain intellectual property universities; and
rights, including patents, for the federal • $109.2 million for NIH-funded clinical trials.
government. Multiple federal agencies
support biomedical research and Figure: Examples of Federal Involvement in the Development of Remdesivir, 2013-2020
development, which can directly or
indirectly contribute to the development
of new drugs like remdesivir. These
federal agencies include NIH—the
largest public funder of biomedical
research in the world—as well as CDC
and DOD.
GAO was asked to review federal
contributions to the development of
remdesivir. This report examines:
(1) scientific and funding contributions
provided by CDC, DOD, and NIH for
the development of remdesivir, and
(2) agencies’ patent rights related to
those contributions. GAO reviewed
relevant laws and regulations;
reviewed documentation from CDC,
DOD, and NIH; and interviewed
officials and scientists from the Federally supported remdesivir research conducted by CDC, DOD, NIH, and
agencies and two universities. We also NIH-funded universities has not resulted in government patent rights, because,
obtained information from and according to agency and university officials, federal contributions to the research
interviewed representatives of Gilead. did not generate new inventions. In addition, Gilead entered research
collaborations with federal agencies and universities with a portfolio of existing
CDC, DOD, NIH, and Gilead provided patents and patent applications, including for the remdesivir compound, which
technical comments, which we
would have left little room for the agencies to generate their own patents. For
incorporated as appropriate.
example, DOD officials told us that when DOD scientists performed antiviral
View GAO-21-272. For more information, testing of remdesivir against Ebola virus, they used standard tests and screening
contact Candice N. Wright, 202-512-6888, methods and did not come up with new tests or methods.
WrightC@gao.gov
United States Government Accountability Office
Contents
Letter 1
Background 3
Federal Agencies Made Contributions to Remdesivir Preclinical
Research and Clinical Trials 8
Federal Researchers Did Not Disclose New Inventions Related to
Remdesivir and Research Did Not Result in Government Patent
Rights 16
Agency Comments and Third-Party Views 19
Appendix I Objectives, Scope, and Methodology 22
Appendix II Federal Agreements and Funding for Remdesivir Research 24
Appendix III Intellectual Property Provisions in Federal Agency
Agreements to Support Remdesivir Research 30
Appendix IV Gilead Sciences’ Remdesivir Patents 32
Appendix V GAO Contact and Staff Acknowledgements 35
Tables
Table 1: CDC, DOD, and NIH Funding for Remdesivir Preclinical
Research and Clinical Trials, 2013-2020 15
Table 2: CDC Agreements and Funding for Remdesivir Research
as of Dec. 31, 2020 24
Table 3: DOD Agreements and Funding for Remdesivir Research
as of Dec. 31, 2020 25
Table 4: NIH Agreements and Funding for Remdesivir Research
as of Dec. 31, 2020 27
Table 5: NIH-funded Clinical Trials Involving Remdesivir as of
Dec. 31, 2020 29
Table 6: Government Intellectual Property Rights in Agreements
with Gilead Sciences, 2013-2020 30
Page i GAO-21-272 Biomedical Research
Table 7: Gilead Sciences’ U.S. Remdesivir Patents as of Dec. 31,
2020 32
Figures
Figure 1: Examples of Pharmaceutical Patents 7
Figure 2: Timeline of Select Events and Federal Contributions to
the Development of Remdesivir 10
Abbreviations
CDC Centers for Disease Control and Prevention
COVID-19 Coronavirus Disease 2019
DOD Department of Defense
FDA Food and Drug Administration
Gilead Gilead Sciences, Inc.
HHS Department of Health and Human Services
MRDC U.S. Army Medical Research and Development Command
NIAID National Institute of Allergy and Infectious Diseases
NIH National Institutes of Health
R&D research and development
USAMRIID U.S. Army Medical Research Institute of Infectious
Diseases
This is a work of the U.S. government and is not subject to copyright protection in the
United States. The published product may be reproduced and distributed in its entirety
without further permission from GAO. However, because this work may contain
copyrighted images or other material, permission from the copyright holder may be
necessary if you wish to reproduce this material separately.
Page ii GAO-21-272 Biomedical Research
Letter
441 G St. N.W.
Washington, DC 20548
March 31, 2021
Congressional Addressees
Multiple federal agencies support biomedical research and development
(R&D), which can directly or indirectly contribute to the development of
new drugs. Preeminent among them is the National Institutes of Health
(NIH), an agency in the Department of Health and Human Services
(HHS). NIH is the largest public funder of biomedical research in the
world, with $35 billion obligated in fiscal year 2018. The Centers for
Disease Control and Prevention (CDC), another HHS agency, and the
Department of Defense (DOD) also play active roles in biomedical R&D.
The federal government’s support includes research funding for
universities, R&D conducted in-house at federal laboratories, and
research collaborations that involve federal laboratories, universities, and
pharmaceutical companies.
Generally, federally funded inventions generated by grantees and
contractors are subject to a government use license. 1 The federal
government’s intellectual property rights may also include ownership or
co-ownership of patented inventions resulting from discoveries made in
research collaborations with universities and industry. These ownership
rights could enable the federal government to use the inventions for
public benefit or collect royalties from industry. 2
Remdesivir is an antiviral drug patented and manufactured by Gilead
Sciences, Inc. (Gilead), a U.S. pharmaceutical company with expertise in
antiviral drug development, which owns a large library of compounds that
1Under the Bayh-Dole Act, a government use license generally provides the federal
government with a nonexclusive, nontransferable, irrevocable, paid-up license to practice
(use) the invention or have the invention practiced throughout the world by or on behalf of
the federal government. See 35 U.S.C. § 202(c)(4). This government use license may not
be available for funding agreements not subject to the Bayh-Dole Act.
2A patent is an exclusive right granted for a fixed period of time to an inventor, which can
be assigned to (owned by) other entities. A patent owner can prevent others from making,
using, selling, or offering for sale the patented invention in the United States, or importing
it into the United States without authorization. A patent owner can license or assign the
patent rights.
Page 1 GAO-21-272 Biomedical Research
target viral pathogens. 3 Originally developed by Gilead as a candidate to
treat viral hepatitis and respiratory syncytial virus infection, remdesivir
was later studied for antiviral activity against multiple virus families,
including coronaviruses. 4
In the spring of 2020, remdesivir was the first drug shown to shorten
recovery time in hospitalized Coronavirus Disease 2019 (COVID-19)
patients and subsequently became the first drug to be approved by the
Food and Drug Administration (FDA) as a COVID-19 treatment. 5 FDA
granted an emergency use authorization on May 1, 2020, and approval
on October 22, 2020, for using remdesivir to treat COVID-19. 6
Policymakers, state authorities, and public interest advocates have raised
concerns about access to remdesivir in the United States. 7
3According to Gilead, the company’s other areas of expertise are hematology, oncology,
and inflammatory diseases; in February 2021 it had more than 25 products on the U.S.
market, of which 17 were antiviral drugs.
4Viral hepatitis is an infection that causes liver inflammation and damage. Several different
viruses, including hepatitis A, B, and C viruses, cause hepatitis. Respiratory syncytial virus
infection is caused by a common respiratory virus that usually causes mild, cold-like
symptoms, but can be serious, especially for infants and older adults. Coronaviruses,
named for the crown-like spikes on their surfaces, are a family of viruses that are common
in people and many different species of animals.
5According to CDC, COVID-19 is a new disease, caused by a novel coronavirus known as
SARS-CoV-2 that has not previously been seen in humans.
6Under section 564 of the Federal Food, Drug, and Cosmetic Act, the FDA Commissioner
may allow unapproved medical products or unapproved uses of approved medical
products to be used in an emergency to diagnose, treat, or prevent serious or life-
threatening diseases or conditions caused by chemical, biological, radiological, and
nuclear threat agents when there are no adequate, approved, and available alternatives.
Following the initial May 1, 2020, emergency use authorization granted to treat
hospitalized adult and pediatric patients with severe COVID-19 disease, FDA broadened
the authorization’s scope to include hospitalized COVID-19 patients, irrespective of the
severity of the disease, on August 28, 2020. On October 22, 2020, FDA approved
remdesivir for the treatment of COVID-19 in adults and pediatric patients (12 years of age
and over weighing at least 40 kg) requiring hospitalization. The emergency use
authorization for remdesivir remains in effect for other pediatric patients not covered by
the approval.
7On June 29, 2020, Gilead announced that it would charge $2,340 for a five-day course
for all governments in the developed world, including the U.S. government’s Medicaid
program and the Department of Veterans Affairs, and $3,120 (or 33 percent more) for
private U.S. insurers. At present, remdesivir is administered intravenously in a hospital
setting. According to Gilead, it is developing inhalable, subcutaneous, and oral forms of
remdesivir, which may affect the drug’s pricing and could involve additional patents and
separate FDA review and approval.
Page 2 GAO-21-272 Biomedical Research
You asked us to review federal contributions to the development of
remdesivir and intellectual property rights associated with them. This
report examines: (1) scientific and funding contributions provided by
federal agencies for the development of remdesivir, and (2) federal
agencies’ patent rights related to those contributions. For both objectives,
we reviewed relevant laws and regulations, and documentation from
CDC, DOD, and NIH. We also interviewed officials and scientists from
CDC, DOD, NIH, the University of North Carolina at Chapel Hill, and
Vanderbilt University. We met with representatives from Gilead and
obtained information about remdesivir development and patents from the
company. (See app. I for more details about our scope and methodology.)
We conducted this performance audit from August 2020 to March 2021 in
accordance with generally accepted government auditing standards.
Those standards require that we plan and perform the audit to obtain
sufficient, appropriate evidence to provide a reasonable basis for our
findings and conclusions based on our audit objectives. We believe that
the evidence obtained provides a reasonable basis for our findings and
conclusions based on our audit objectives.
Background
Drug Development The development and approval of a new drug is a long and costly process
that can take 15 or more years and can involve multiple public and private
entities that fund and conduct R&D. 8 Typically, this process consists of
the following stages:
• Basic research. Scientific investigation of the molecular, cellular, or
biological mechanisms of a disease that lays the foundation for the
development of new drugs;
• Drug discovery. Screening of thousands of compounds in the
laboratory to identify promising candidates to treat the disease;
8The cost of developing a new drug is a subject of debate. A study published in 2016
estimated the cost of developing a new drug at more than $2.5 billion; see J.A. DiMasi,
H.G. Grabowski, and R.W. Hansen, “Innovation in the Pharmaceutical Industry: New
Estimates of R&D Costs.” Journal of Health Economics, vol. 47 (2016). A more recent
study estimated the cost at $1.3 billion; see O.J. Wouters, M. McKee, and J. Luyten,
“Estimated Research and Development Investment Needed to Bring a New Medicine to
Market, 2009-2018,” Journal of the American Medical Association, vol. 323, no. 9 (2020).
Page 3 GAO-21-272 Biomedical Research
• Preclinical research. Laboratory and animal testing to further narrow
the list of compounds and answer basic questions about safety and
proof of concept;
• Clinical trials. Testing of the drug in human volunteers for safety and
efficacy that is conducted in phases; 9 and
• Review and approval. FDA conducts a regulatory review before
approving, or declining to approve, the drug for marketing and sales in
the United States.
During this process, many new drug candidates fail to advance to the
next stage or to gain FDA approval. Often, drug candidates and drugs
that already have FDA approval are studied for new therapeutic uses.
Because such work builds upon previous R&D efforts, new candidate
therapies could be ready for clinical trials quickly, speeding their review
by FDA. Gilead originally invented and developed remdesivir as a
candidate for treating viral hepatitis and respiratory syncytial virus
infection; however, it was never approved for either disease. Remdesivir
was subsequently investigated for its antiviral potential for several other
viruses, as discussed in this report, before FDA approved it as a COVID-
19 treatment in October 2020.
9Clinical trials are usually conducted in phases that build on one another. Phase I trials of
a new drug are usually the first that involve human volunteers and are done to find the
highest dose of the new treatment that can be given safely without causing severe side
effects. If a new treatment is found to be safe in phase I clinical trials, a phase II clinical
trial is conducted to investigate its efficacy against a disease. Phase III clinical trials
compare the safety and efficacy of the new treatment against the current standard
treatment or a placebo. Phase IV clinical trials study the side effects caused over time by
a new treatment after it has been approved and is on the market.
Page 4 GAO-21-272 Biomedical Research
Public Funding for Federal funding for life sciences, which include biological and medical
Biomedical R&D sciences, accounts for about 29 percent of federally supported R&D.
According to the most recent data from the National Science Foundation,
the federal government obligated $129 billion for R&D, including $37
billion for life sciences, in fiscal year 2018 (see sidebar). 10 NIH is the
largest source of support; it directs funding to universities and supports
research performed by government scientists at NIH laboratories. At NIH,
the National Institute of Allergy and Infectious Diseases (NIAID) is the
leading institution for carrying out and supporting research on infectious
diseases caused by viral pathogens.
Other agencies—such as CDC, DOD, and the Department of Veterans
Affairs—also support biomedical R&D. CDC, which leads outbreak and
emergency responses domestically and abroad, has several laboratories
across the United States that perform biomedical R&D and public health
research. At DOD, several components support biomedical R&D,
including the Joint Program Executive Office for Chemical, Biological,
Radiological and Nuclear Defense and the U.S. Army Medical Research
and Development Command (MRDC). DOD’s lead laboratory for
biomedical defense research is the U.S. Army Medical Research Institute
of Infectious Diseases (USAMRIID), which is subordinate to MRDC.
Another significant contribution that the federal government makes to
biomedical R&D is specialized facilities. For example, some federal
laboratories contain biohazard containment systems that are uncommon
outside the federal government. These facilities enable federal scientists
to study the world’s most dangerous pathogens, including Ebola and
other viruses. 11
10National Science Foundation, Survey of Federal Funds for Research and Development,
Fiscal Years 2018–19, https://ncsesdata.nsf.gov/fedfunds/2018/, accessed Feb. 23, 2021.
11Ebola virus is one of several filoviruses that cause a deadly hemorrhagic fever in
humans and nonhuman primates, such as monkeys, gorillas, and chimpanzees, with
occasional outbreaks that occur primarily on the African continent. According to CDC,
people can get the disease through direct contact with an infected animal, or a sick or
dead person infected with Ebola virus.
Page 5 GAO-21-272 Biomedical Research
A recent paper seeks to quantify the relationship between NIH-funded
basic research and the development of remdesivir and other drugs with
similar chemical structure (see sidebar). 12 According to the paper, two
bodies of foundational research enabled the development of drugs like
remdesivir: studies of nucleoside analogs, drugs with remdesivir’s parent
chemical structure, and studies of RNA-dependent RNA polymerase,
remdesivir’s biological target. It estimates that NIH provided $6.5 billion
from 2000 through 2019 to support these two bodies of basic research.
According to officials from NIAID we spoke with, the paper’s interpretation
of the remdesivir-enabling foundational research is broad, and the
estimate includes research for other drugs with similar targets and
mechanisms of action as remdesivir. They also told us that NIAID did not
have its own estimate of NIH funding for basic research that enabled the
development of remdesivir.
Patent Rights for If an inventor invents or discovers a new chemical compound, the
Inventions Developed with inventor may seek a patent claiming the invention. 13 An inventor can also
Federal Support patent a group of distinct chemical compounds. Also patentable are drug
formulations, methods of using a drug to treat a particular disease,
methods and technologies to administer or manufacture a drug, as well
as methods and technologies that test for and diagnose diseases, if they
meet certain patentability requirements. See figure 1 for examples of
pharmaceutical patents. 14
12E.G. Cleary et al., “Foundational Research and NIH Funding Enabling Emergency Use
Authorization of Remdesivir for COVID-19,” medRxiv. Pre-print version, posted July 6,
2020, doi: https://doi.org/10.1101/2020.07.01.20144576. The study had not been peer-
reviewed as of March 2021. An earlier study by some of the same authors observed that
while estimates exist for the commercial development of new drugs, the public sector
contribution to new drugs is less well quantified; E.G. Cleary et al., “Contribution of NIH
Funding to New Drug Approvals 2010-2016,” PNAS, vol. 115, no. 10 (2018).
13See generally 35 U.S.C. § 101.
14Under U.S. patent law, any person who “invents or discovers any new and useful
process, machine, manufacture, or composition of matter” may apply for a patent on the
invention with the U.S. Patent and Trademark Office (USPTO). If the USPTO patent
examiner concludes that the claimed invention is novel, nonobvious, useful, directed at
patentable subject matter, and adequately disclosed and claimed, USPTO will issue a
patent. Patents typically expire 20 years after the initial patent application is filed.
Page 6 GAO-21-272 Biomedical Research
Figure 1: Examples of Pharmaceutical Patents
When an invention is conceived and reduced to practice by a company
that has received federal support for that invention, any resulting patent
rights are owned jointly or separately by the U.S. government or the
Page 7 GAO-21-272 Biomedical Research
company, depending on the nature of federal involvement in the
invention. 15 The federal government uses different types of agreements to
support R&D conducted by nonfederal entities, such as universities or
pharmaceutical companies, and collaborations with such entities. Some
agreements, including contracts, grants, cooperative agreements, and
“other transaction” authority agreements involve the transfer of federal
funding to nonfederal entities. 16 Other agreements, such as cooperative
research and development agreements and material transfer agreements,
do not. 17
Beginning in 2013, CDC, DOD, and NIH supported and conducted
Federal Agencies preclinical research collaborations with Gilead that helped to demonstrate
Made Contributions to remdesivir’s broad-spectrum antiviral properties against multiple viruses,
including coronaviruses and Ebola. Later, data from NIH-supported
Remdesivir clinical trials helped to advance remdesivir to clinical use once the
Preclinical Research COVID-19 pandemic reached the United States. Federal funding for
these remdesivir preclinical studies and clinical trials totaled $161.5
and Clinical Trials million.
15The federal government’s general policy for federally owned inventions, under the
Stevenson-Wydler Technology Innovation Act and the Federal Technology Transfer Act of
1986, is to encourage commercialization by licensing federally owned patent rights to
private parties—a process called “technology transfer.”
16A federal agency can use a contract under the Federal Acquisition Regulation to procure
and pay for property or services, including research services, from a private company. It
can use a grant to fund university-based research or a cooperative agreement to fund a
complex or targeted research study conducted by a university consortium. Some
agencies, including DOD and NIH, have the authority to enter into “other transaction”
authority agreements. “Other transactions” may be exempt from many statutory provisions
and procurement regulations, such as the Bayh-Dole provision granting a government use
license for federally funded inventions. See 35 U.S.C. § 202(c)(4).
17A federal laboratory can use a cooperative research and development agreement to
provide personnel, services, facilities, or other resources, while the nonfederal collaborator
(a company or academic institution) provides funds, personnel, services, facilities, or other
resources toward a specific R&D project. A material transfer agreement can be used to
transfer a specialized or experimental material between a federal laboratory and another
party for commercial evaluation, testing, or other uses.
Page 8 GAO-21-272 Biomedical Research
CDC, DOD, and NIH The federal government began supporting Gilead’s preclinical remdesivir-
Helped to Advance the related research in 2013 (see fig.2), when Gilead provided three
compounds, including remdesivir’s parent compound, to CDC for antiviral
Knowledge of
screening. CDC, DOD, and NIH began supporting research focusing on
Remdesivir’s Antiviral remdesivir itself in 2014. By that time, Gilead had invented the compound;
Activity against the company first synthesized the parent compound in March 2009. The
Coronaviruses, Ebola company isolated the remdesivir compound in 2013. According to Gilead,
Virus, and Other between 2009 and 2013, the company conducted and funded preclinical
research that first identified and confirmed the antiviral activity of
Pathogens remdesivir and its parent compound against coronaviruses and other
viruses. Gilead also began patenting the compounds during this period.
Page 9 GAO-21-272 Biomedical Research
Figure 2: Timeline of Select Events and Federal Contributions to the Development of Remdesivir
Preclinical Research When Gilead initiated preclinical research collaborations with CDC in
2013 and with DOD’s USAMRIID in 2014, Gilead scientists selected
Page 10 GAO-21-272 Biomedical Research
compounds for testing against emerging viruses. 18 CDC and USAMRIID
scientists investigated remdesivir for antiviral activity against Ebola and
other pathogens. These collaborations took place at the time of several
outbreaks of Ebola virus disease affecting multiple countries. 19 According
to CDC and USAMRIID scientists we interviewed, most of their research
took place at these agencies’ Biosafety Level 4 facilities, because it
involved very dangerous pathogens. 20
CDC began its research collaboration with Gilead in 2013 by screening
three Gilead-owned compounds, including remdesivir’s parent compound
GS-441524, for antiviral activity against Nipah or Hendra viruses. 21
According to Gilead, the company selected the compounds based on its
proprietary knowledge about the compounds’ antiviral profiles and
requested that CDC evaluate them for antiviral activity against multiple
viruses. In 2014, as an Ebola virus disease outbreak was taking place in
West Africa, CDC scientists at the National Center for Emerging and
Zoonotic Infectious Diseases proposed to test the parent compound GS-
441524 against Ebola and found that it exhibited antiviral activity against
the virus. 22 Later, the collaboration expanded to screening 73 Gilead-
owned compounds, which included remdesivir. As described in one of the
first scientific publications about remdesivir, CDC scientists designed and
executed the initial antiviral testing of remdesivir in cell cultures for
18Gilead initially provided the compounds to CDC and USAMRIID blinded, meaning that
only Gilead knew what the compounds were.
19Multiple outbreaks of Ebola virus disease occurred between 2012 and 2020, according
to CDC. The 2014-2016 outbreak, which generated the largest number of infections and
deaths, spread from Africa to Europe and the United States.
20Biosafety Level 4 is the highest level of biosafety precaution.
21Nipah and Hendra are related viruses that spread between animals and people.
According to CDC, Nipah virus kills about 75 percent of people it infects.
22Gilead provided the compounds blinded, meaning that CDC scientists did not know what
the compounds were at the time.
Page 11 GAO-21-272 Biomedical Research
efficacy against Ebola virus. 23 CDC scientists also evaluated remdesivir’s
antiviral properties against other virus families. 24
At DOD, USAMRIID’s collaboration with Gilead, which began in 2014,
involved the screening of more than 1,000 Gilead-owned compounds for
antiviral activity against multiple viruses. USAMRIID scientists told us
that, as the research progressed, they collaborated closely with Gilead
scientists to advance multiple promising compounds, including
remdesivir, from testing in cell cultures to nonhuman primate testing with
live Ebola virus. USAMRIID research demonstrated remdesivir’s activity
against Ebola in primates and generated data that could support further
investigation of remdesivir as an Ebola treatment for humans. Similar to
research conducted by CDC scientists, USAMRIID scientists also tested
remdesivir for activity against other viruses. 25
NIH support for remdesivir research involved funding for extramural
research at universities beginning in 2014 as well as conducting its own
intramural research beginning in 2016. 26 Most of the preclinical remdesivir
research funded and conducted by NIH focused on coronaviruses.
According to Gilead, the company had already determined that
remdesivir’s parent compound and remdesivir itself were active against
some coronaviruses by the time NIH began supporting remdesivir
coronavirus research: research conducted or funded by Gilead
demonstrated that remdesivir’s parent compound and remdesivir were
active against the severe acute respiratory syndrome-associated
23Travis K. Warren et al., “Therapeutic Efficacy of the Small Molecule GS-5734 against
Ebola Virus in Rhesus Monkeys,” Nature, vol. 531 (2016). The article was co-authored by
scientists from multiple organizations, including CDC, Gilead, and USAMRIID. Before
publication, initial results were reported in an October 2015 presentation at the joint
annual meeting (IDWeek) of the Infectious Diseases Society of America, Society for
Healthcare Epidemiology of America, HIV Medical Association, Pediatric Infectious
Diseases Society, and Society of Infectious Diseases Pharmacists.
24These virus families included other filoviruses (Ebola is a filovirus), paramyxoviruses,
arenaviruses, and flaviviruses, among others. According to Gilead, the company had
funded similar screenings of its compounds prior to the collaboration with CDC.
25These viruses included Chikungunya, Rift Valley fever virus, and the Middle East
respiratory syndrome coronavirus (MERS-CoV). In addition, according to DOD officials, as
of January 2021, USAMRIID was planning to investigate remdesivir’s potential against
Marburg virus, which, similar to Ebola, causes a hemorrhagic fever.
26Federally funded R&D performed at universities, medical centers, hospitals, and other
research institutions is known as extramural; R&D conducted by federal agencies at their
own laboratories and facilities is known as intramural.
Page 12 GAO-21-272 Biomedical Research
coronavirus (SARS-CoV) in 2012 and the Middle East respiratory
syndrome coronavirus (MERS-CoV) in 2013.
NIH-funded university-based remdesivir preclinical research was
conducted by scientists at the University of North Carolina at Chapel Hill
and Vanderbilt University in collaboration with Gilead scientists. 27 The
research confirmed remdesivir’s antiviral potential against known
coronaviruses and demonstrated that it could be active against new
coronaviruses. 28 Research performed by NIH scientists at NIAID’s
Laboratory of Virology between 2016 and 2020 involved preclinical testing
of remdesivir in nonhuman primate models of coronavirus infection and
disease and necessitated use of specialized facilities for handling
dangerous pathogens.
Clinical Trials and FDA NIH supported three clinical trials involving remdesivir—two for Ebola
Approval virus disease in 2016-2019 and a COVID-19 trial in 2020:
• Ebola trials known as PREVAIL IV and PALM. After remdesivir
showed promise against Ebola virus in preclinical studies, it was
tested for safety and efficacy in Ebola clinical trials without becoming
an FDA-approved treatment. The PREVAIL IV and PALM trials helped
to generate safety and efficacy data for using remdesivir in human
patients. 29 Before these trials, Gilead initiated its own phase I trials to
evaluate the safety and chemical behavior of remdesivir in humans. 30
Although the PALM trial showed that remdesivir was less efficacious
against Ebola virus disease than another treatment, the two trials
helped to establish that remdesivir was safe to use in human patients
27The research was conducted as part of a university consortium research project led by
the University of Alabama at Birmingham. In addition to coronaviruses, the project
investigated three other virus families.
28See, for example, T.P. Sheahan et al., “Broad-Spectrum Antiviral GS-5734 Inhibits both
Epidemic and Zoonotic Coronaviruses,” Science Translational Medicine, vol. 9, no. 396
(2017).
29The Partnership for Research on Ebola Virus in Liberia IV (PREVAIL IV) trial was a
phase II trial. The Pamoja Tulinde Maisha (PALM), translated as “together save lives,”
was a phase II and phase III trial. Prior to PREVAIL IV and PALM, Gilead had funded or
conducted several phase I trials.
30According to Gilead, the phase I safety and chemical behavior (known as
pharmacokinetics) studies in humans were considerably expanded in 2016 and then again
in 2019 to include an assessment of additional remdesivir formulations, doses, and
duration of treatment.
Page 13 GAO-21-272 Biomedical Research
and generated additional safety data that could be reviewed by
FDA. 31
• The Adaptive COVID-19 Treatment Trial (ACTT). This multi-stage
trial was initiated in February 2020. 32 ACTT is an ongoing phase III
trial, which was preceded by phase I and II trials involving remdesivir,
including Gilead-funded trials as well as PREVAIL IV and PALM that
established its safety for human use. Preliminary results of ACTT’s
first stage released in April 2020 showed that remdesivir shortened
recovery time in hospitalized patients with severe COVID-19. Based in
part on those results, FDA granted an emergency use authorization
on May 1, 2020, for using remdesivir to treat such patients. 33 FDA
also cited the trial’s data, along with data from trials conducted by
Gilead, in its approval of remdesivir granted on October 22, 2020. 34
Federal Funding Federal agencies contributed $161.5 million to remdesivir R&D from 2013
Supported Remdesivir through 2020. As of December 31, 2020, CDC had provided $0.7 million
and DOD had provided $39.7 million to support research on Ebola and
Preclinical Research and
other viruses, and NIH had provided $121.1 million to support
Clinical Trials coronavirus-focused preclinical research and three clinical trials that
involved remdesivir. Table 1 summarizes the funding information for
CDC, DOD, and NIH. (These agencies are continuing to fund and
conduct remdesivir research; see app. II for more details about each
agency’s funding for remdesivir research and agreements to provide
funding). In addition to funding, the three agencies made an important
contribution by providing federal Biosafety Level 4 facilities for testing
remdesivir against dangerous pathogens such as Ebola virus.
31According to Gilead, because Ebola (a filovirus that is spread via body fluids) and
coronaviruses (spread via respiratory droplets) are very different, research into the
efficacy of remdesivir against Ebola virus disease was of limited utility in assessing the
drug’s efficacy for treating COVID-19.
32As of January 2021, there were four stages of ACTT; the last stage began in November
2020. All four stages of the trial involved remdesivir.
33FDA cited efficacy data from three COVID-19 trials in its emergency use authorization—
ACTT and two trials conducted by Gilead—noting that ACTT had generated the most
robust clinical data.
34The preliminary and final results of ACTT’s first stage were published in The New
England Journal of Medicine. For final results, see J.H. Beigel et al., “Remdesivir for the
Treatment of Covid-19—Final Report,” The New England Journal of Medicine, vol. 383,
no. 19 (2020).
Page 14 GAO-21-272 Biomedical Research
Table 1: CDC, DOD, and NIH Funding for Remdesivir Preclinical Research and Clinical Trials, 2013-2020
Type of research Amount by agency (in millions $) Totals
CDC DOD NIH
Preclinical research 0.7 39.7 11.9 52.3
Clinical trials ─ ─ 109.2 109.2
Total 0.7 39.7 121.1 161.5
Source: GAO analysis of documents and information from the Centers for Disease Control and Prevention (CDC), Department of Defense (DOD), and National Institutes of Health (NIH). | GAO-21-272
Note: The amounts in the table reflect funding for intramural and extramural research as of Dec. 31,
2020.
According to Gilead representatives, Gilead did not rely on any federal
contributions in conducting its own research that led to the invention of
remdesivir and invested $786 million in remdesivir R&D from 2000
through December 2020. 35 Gilead representatives also told us that the
company made substantial contributions to the research performed in the
collaborations with federally funded scientists, which was corroborated in
our interviews with others. For example, principal investigators of the NIH-
funded coronavirus research told us that scientists at Vanderbilt
University and the University of North Carolina at Chapel Hill worked in
close collaboration with Gilead scientists. A principal investigator also
noted that Gilead had dedicated substantial resources and maintained a
coronavirus research team for several years prior to the COVID-19
pandemic when few others were interested in studying coronaviruses.
35Gilead estimated its overall investment in remdesivir, as of December 2020, at $1.3
billion. According to the company, of the $786 million in R&D costs, Gilead spent $215
million on the discovery and development of remdesivir prior to 2020, of which $175
million is attributable specifically to R&D costs and $40 million to costs of supplying
remdesivir for use in NIH clinical trials and other clinical and research settings. Gilead told
us that in addition to the R&D costs the company spent $147 million to supply remdesivir
for use in clinical and research settings and $318 million to expand remdesivir
manufacturing and distribution capabilities, as of December 2020.
Page 15 GAO-21-272 Biomedical Research
Intellectual property provisions in agreements negotiated with Gilead
Federal Researchers generally would have allowed the agencies to pursue patents, had the
Did Not Disclose New remdesivir research supported and conducted by CDC, DOD, and NIH
resulted in new inventions. 36 However, remdesivir research supported or
Inventions Related to conducted by CDC, DOD, and NIH has not resulted in government patent
Remdesivir and rights, because, according to agency and university officials, the federal
contributions to the research did not generate new patentable
Research Did Not discoveries, and Gilead already had existing patents on remdesivir.
Result in Government According to DOD and NIH officials, while the federally supported
remdesivir research did not result in patent rights for the federal
Patent Rights government, it helped to deliver a needed drug to the public.
Some scholars and public interest advocates have suggested that CDC
or DOD scientists may be co-inventors on some of Gilead’s remdesivir
patents. 37 The suggestions were based in part on contributions to
remdesivir research on Ebola as described in published scientific studies
that CDC and USAMRIID scientists co-authored with Gilead scientists. 38
The CDC, DOD, NIH, and university officials we interviewed stated that
federal and university scientists who conducted remdesivir research did
not file invention disclosures, which would have been a precursor to filing
a patent. 39 Further, according to DOD, NIH, and universities, their
36See app. III for more details about the intellectual property provisions of the agencies’
agreements with Gilead.
37See J. Hughes and A. Rai, “Acknowledging the Public Role in Private Drug
Development: Lessons from Remdesivir,” STAT (May 8, 2020); J. Krellenstein and C.J.
Morten, “The U.S. Government’s Apparent Co-Ownership of Patents Protecting
Remdesivir,” The PrEP4All Collaboration and New York University School of Law (May
20, 2020); C. Rowland, “Taxpayers Paid to Develop Remdesivir but Will Have No Say
when Gilead Sets the Price, Washington Post (May 26, 2020); and E. Silverman, “A
Payoff for U.S. Taxpayers? CDC May Have Claims on Remdesivir Patents Held by
Gilead,” STAT (Dec. 7, 2020).
38The standards for co-inventorship are different from those for co-authorship. Co-
authorship, which is determined by each publication and can vary, generally includes
those who contributed to the research. Co-inventorship requires contribution to the
conception of the invention.
39An invention disclosure—a form in which scientists document their inventions—is the
initial step in the process that federal agencies and universities use for managing their
intellectual property. Technology transfer and intellectual property law staff review
invention disclosures and consider whether the invention is patentable. They also consider
whether patenting the invention is likely to result in a successful commercialization or
other practical application before deciding whether to pursue a patent in the United States
and other countries.
Page 16 GAO-21-272 Biomedical Research
scientists were not co-inventors of patented remdesivir discoveries for
reasons outlined below:
• According to MRDC officials at DOD, USAMRIID scientists had not
submitted any invention disclosures from their remdesivir research.
Further, MRDC conducted an inventorship analysis in the spring of
2020 in response to questions raised by intellectual property scholars
and public advocates cited above about the government’s possible
co-inventorship of remdesivir. MRDC determined that scientific work
performed by USAMRIID scientists did not rise to the level of co-
inventor status on any of Gilead’s remdesivir patents. MRDC officials
told us that they reached this determination based on the following
factors: (1) Gilead invented the remdesivir compound and determined
that it had antiviral activity against hepatitis C virus prior to the
company’s collaboration with DOD; (2) Gilead entered into its
collaboration with DOD with rights to all remdesivir and other
compounds it provided, and told USAMRIID scientists what the
compounds should be screened for; and (3) when USAMRIID
scientists performed antiviral testing of remdesivir against Ebola virus,
they used standard tests and screening methods and did not come up
with new types of tests or screenings. 40
• According to NIH officials, NIH scientists did not submit invention
disclosures from their coronavirus-focused remdesivir research, and
invention disclosures were unlikely to emerge because Gilead had
already determined that remdesivir exhibited antiviral activity against
coronaviruses before NIH began its research. NIH officials told us
that, given these circumstances, NIH did not conduct an inventorship
analysis.
• The principal investigators of NIH-funded coronavirus research
projects told us that they did not consider filing invention disclosures
because their research did not involve making any modifications to
remdesivir or its parent compounds. The principal investigators stated
that they viewed such modifications as the threshold for filing such
disclosures.
40MRDC officials further elaborated that the tests and screening methods used by
USAMRIID scientists in their remdesivir research collaborations with Gilead were known
and established. According to these officials, for inventorship criteria to be met, a
USAMRIID scientist would have had to deviate significantly from the statements of work in
agreements with Gilead. The officials stated that USAMRIID scientists did not contribute
toward the conception of remdesivir or using remdesivir to treat Ebola or any other
viruses.
Page 17 GAO-21-272 Biomedical Research
DOD and NIH officials also told us that Gilead’s prior remdesivir research
and intellectual property portfolio left few opportunities for federally
supported scientists to make new patentable discoveries:
• Gilead entered the research collaborations with the federal agencies
and universities with its portfolio of existing patents and patent
applications, including for the remdesivir compound. NIH officials
stated that Gilead began patenting methods of using remdesivir to
treat coronavirus infections in 2015, that is, before NIH scientists
began their remdesivir research focusing on coronaviruses in 2016.
The company continued to expand its portfolio during collaborations
with federally supported scientists. For example, Gilead applied for an
Ebola-related remdesivir patent during its research collaborations with
CDC and DOD’s USAMRIID. Separate from federally supported
collaborations Gilead conducted its own remdesivir research and,
according to Gilead, patented inventions resulting from that research,
such as various formulations of remdesivir. 41 As of December 2020,
Gilead owned 16 U.S. patents, including six that claimed the
molecular structure of remdesivir and parent compounds, and
submitted eight remdesivir-related patent applications, according to
the company. Gilead representatives stated that the company’s
scientists are the sole inventors of the discoveries claimed in those 16
remdesivir patents. (For more information about Gilead’s remdesivir
patents, see app. IV.)
• DOD and NIH officials told us that even if federal scientists had
submitted invention disclosures for new methods of using remdesivir,
Gilead’s remdesivir compound patents would have reduced the value
of method-of-use patents to the federal government. According to
DOD and NIH officials, a remdesivir method-of-use patent would be of
low economic value because the federal government did not own the
compound patents and would have had to license those patents from
Gilead if it wanted to commercialize the method of use or license it to
another company. DOD officials also told us that such follow-on
patents would be hard to obtain and enforce.
With respect to CDC, officials told us that their scientists had not filed
invention disclosures from their remdesivir research that began in 2014.
CDC scientists told us that at the time of their research they were focused
on determining if remdesivir had the potential to become an effective
treatment for Ebola virus disease in response to ongoing Ebola outbreaks
41Larson, Nate. Compositions Comprising an RNA Polymerase Inhibitor and Cyclodextrin
for Treating Viral Infections. U.S. Patent 10,675,296, filed July 11, 2017, and issued June
9, 2020.
Page 18 GAO-21-272 Biomedical Research
in Africa, without immediate consideration of the intellectual property
implications. According to officials, as of March 2021, it was unlikely that
CDC would conduct an inventorship analysis or pursue intellectual
property rights given Gilead’s background intellectual property and the
limited potential for CDC to license any such rights. 42
We provided a draft of this report to CDC, DOD, NIH, and Gilead. They
Agency Comments provided technical comments, which we incorporated as appropriate.
and Third-Party
Views
We are sending copies of this report to the appropriate congressional
committees, the Secretary of Health and Human Services, the Secretary
of Defense, Chief Executive Officer of Gilead, and other interested
parties. In addition, the report is available at no charge on the GAO
website at http://www.gao.gov.
If you or your staff have questions about this report, please contact me at
(202) 512-6888 or WrightC@gao.gov. Contact points for our Offices of
Congressional Relations and Public Affairs may be found on the last page
of this report. Key contributors to this report are listed in appendix V.
Candice N. Wright
Acting Director
Science, Technology Assessment, and Analytics
42CDC officials further explained that generally the agency undertakes an inventorship
analysis if there is disagreement among the involved parties about who the inventors
should be, or if there is knowledge of an invention for which another party had filed a
patent application and for which CDC scientists may be inventors, among other factors.
Page 19 GAO-21-272 Biomedical Research
List of Addressees
The Honorable Patrick Leahy
Chairman
The Honorable Richard Shelby
Vice Chairman
Committee on Appropriations
United States Senate
The Honorable Ron Wyden
Chairman
The Honorable Mike Crapo
Ranking Member
Committee on Finance
United States Senate
The Honorable Patty Murray
Chair
The Honorable Richard Burr
Ranking Member
Committee on Health, Education,
Labor, and Pensions
United States Senate
The Honorable Gary C. Peters
Chair
The Honorable Rob Portman
Ranking Member
Committee on Homeland Security
and Governmental Affairs
United States Senate
The Honorable Debbie Stabenow
Chair
Subcommittee on Health Care
Committee on Finance
United States Senate
Page 20 GAO-21-272 Biomedical Research
List of Addressees Continued
The Honorable Rosa L. DeLauro
Chairwoman
The Honorable Kay Granger
Ranking Member
Committee on Appropriations
House of Representatives
The Honorable Frank Pallone, Jr.
Chairman
The Honorable Cathy McMorris Rodgers
Republican Leader
Committee on Energy and Commerce
House of Representatives
The Honorable Bennie G. Thompson
Chairman
The Honorable John Katko
Ranking Member
Committee on Homeland Security
House of Representatives
The Honorable Carolyn B. Maloney
Chairwoman
The Honorable James Comer
Ranking Member
Committee on Oversight and Reform
House of Representatives
The Honorable Richard Neal
Chair
The Honorable Kevin Brady
Republican Leader
Committee on Ways and Means
House of Representatives
Page 21 GAO-21-272 Biomedical Research
Appendix I: Objectives, Scope, and
Appendix I: Objectives, Scope, and
Methodology
Methodology
We reviewed federal contributions to the development of the antiviral drug
remdesivir and intellectual property rights associated with them.
Specifically, this report examines: (1) scientific and funding contributions
provided by the Centers for Disease Control and Prevention (CDC),
Department of Defense (DOD), and National Institutes of Health (NIH) for
the development of remdesivir, and (2) these agencies’ patent rights
related to those contributions.
To address these objectives, we reviewed relevant statutes and
regulations, and documentation from CDC, DOD, and NIH. We
interviewed officials and scientists from CDC, DOD, NIH, the University of
North Carolina at Chapel Hill, and Vanderbilt University. We obtained
information from and interviewed representatives of Gilead Sciences, Inc.
(Gilead), the pharmaceutical company that manufactures remdesivir. We
also interviewed intellectual property scholars and public interest
organization representatives.
To examine the agencies’ scientific and funding contributions, we
obtained funding information for extramural and intramural remdesivir
research and agreements CDC, DOD, and NIH used to support this
research for the period 2013 through 2020. We analyzed the sections of
the agreements that described study plans, the parties’ responsibilities,
and budgets. To assess the reliability of the agencies’ funding
information, we interviewed knowledgeable agency officials about how
that information was generated and compared the funding estimates the
agencies provided with the funding in the agreements, where appropriate.
We determined that the agencies’ funding information was reliable for the
purposes of this report. We reviewed publicly available regulatory
information from the Food and Drug Administration (FDA) regarding
remdesivir’s emergency use authorization and approval. We also
conducted a literature search to identify published remdesivir research. A
GAO research librarian searched various research databases—including
ProQuest and Scopus, among others—to identify scholarly and peer-
reviewed publications about remdesivir published as of October 30, 2020.
Our search terms included “remdesivir” and “GS-5734.”
To examine patent rights related to CDC, DOD, and NIH scientific and
funding contributions, we analyzed the agreements used by the agencies
to support remdesivir research. The agencies identified 24 such
agreements in effect since 2013: 13 of them were between one of the
three federal agencies and Gilead; the other 11 were between one of the
Page 22 GAO-21-272 Biomedical Research
Appendix I: Objectives, Scope, and
Methodology
agencies and a university. 1 We reviewed intellectual property provisions
in the 13 agreements between the federal government and Gilead to
determine whether each agreement contained (1) general intellectual
property provisions that recognize an agency’s existing intellectual
property rights and ability to patent inventions; (2) provisions for subject
inventions granting the government patent or license rights to inventions
made by an agency’s scientists, Gilead’s scientists, or both; (3) provisions
for government licensing rights to Gilead’s existing patents or patentable
inventions resulting from the research; and (4) provisions for government
rights to technical, scientific, or regulatory data.
Gilead provided a list of its remdesivir-related patents issued and
applications submitted to the U.S. Patent and Trademark Office as of
December 31, 2020. We reviewed FDA’s Orange Book to identify
Gilead’s patents for Veklury, the brand name under which Gilead
obtained an FDA approval for remdesivir to treat COVID-19. 2
We conducted this performance audit from August 2020 to March 2021 in
accordance with generally accepted government auditing standards.
Those standards require that we plan and perform the audit to obtain
sufficient, appropriate evidence to provide a reasonable basis for our
findings and conclusions based on our audit objectives. We believe that
the evidence obtained provides a reasonable basis for our findings and
conclusions based on our audit objectives.
1Of the 24 agreements, 22 took effect during the period from 2013 through Dec. 31, 2020,
and 2 agreements between NIH and two universities are taking effect in 2021.
2FDA’s publication Approved Drug Products with Therapeutic Equivalence Evaluations
(commonly known as the Orange Book) identifies drug products approved on the basis of
safety and effectiveness under the Federal Food, Drug, and Cosmetic Act and patents
associated with them: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm,
accessed Nov. 30, 2020.
Page 23 GAO-21-272 Biomedical Research
Appendix II: Federal Agreements and Appendix II: Federal Agreements and Funding
for Remdesivir Research
Funding for Remdesivir Research
This appendix provides information about Centers for Disease Control
and Prevention (CDC), Department of Defense (DOD), and National
Institutes of Health (NIH) agreements and funding for remdesivir
research. These agencies signed multiple agreements with Gilead
Sciences, Inc. (Gilead) and other entities, with some agreements
involving the transfer of federal funding. CDC, DOD, and NIH also
conducted intramural remdesivir research and provided information for
associated costs, which are obligations or expenditures.
CDC Agreements and CDC identified five material transfer agreements related to its remdesivir
Funding for Remdesivir research (table 2), including three agreements between CDC and Gilead.
Each of the five agreements involved the transfer of materials between
Research
the partner organizations for research purposes and did not involve the
transfer of federal funding. CDC is continuing to conduct remdesivir
research. CDC estimated the cost of its intramural remdesivir research
associated with these agreements from 2013 through December 31,
2020, at $726,000, which included staff salary time, laboratory equipment,
supplies, maintenance agreements, and cost sharing of agency
laboratory spaces.
Table 2: CDC Agreements and Funding for Remdesivir Research as of Dec. 31, 2020
Agreement type and Effective Funding
research description date CDC partner CDC role (in millions $)
Material transfer agreement 2/22/2013 Gilead Sciences Recipient of ─a
NCEZID-V126727 compounds from
Preclinical studies of multiple compounds for Gilead Sciences
antiviral activity against several virus families
Material transfer agreement 5/24/2016 Gilead Sciences Provider of ─a
D-389-16 materials to
Characterization of the mechanism of action of Gilead Sciences
remdesivir for treatment of Ebola virus infection
Material transfer agreement 10/16/2018 Uniformed Services Recipient of ─a
D-929-18 University of the Health monoclonal
Assessment of the combination of monoclonal Sciences (USU) antibodies from
antibodies with remdesivir in cell cultures for the USU
evidence of additive or synergistic antiviral effect
Material transfer agreement 9/9/2020 Gilead Sciences Recipient of ─a
D-541-20 compounds from
Development of colorimetric and chromatographic Gilead Sciences
assays for testing to identify counterfeits and poor
quality product
Page 24 GAO-21-272 Biomedical Research
Appendix II: Federal Agreements and Funding
for Remdesivir Research
Agreement type and Effective Funding
research description date CDC partner CDC role (in millions $)
Material transfer agreement 10/7/2020 University of California Recipient of ─a
D-684-20 at San Diego (UCSD) compounds from
Testing of remdesivir analog compounds and their UCSD
ability to block viral replication of SARS-CoV-2 and
hemorrhagic fever viruses in infected tissue culture
cellsb
Total 0.7a
Source: GAO analysis of documents and funding information from the Centers for Disease Control and Prevention (CDC). | GAO-21-272
a
CDC estimated the cost of its intramural remdesivir research associated with all the agreements
listed in the table at $726,000 as of Dec. 31, 2020.
b
Analog compound is a chemical compound that has a similar structure and similar chemical
properties to those of another compound, but differs from it by a single element or group.
DOD Agreements and DOD identified six agreements and one intramural research project
Funding for Remdesivir involving remdesivir (table 3). Three agreements and the intramural
research project involved the U.S. Army Medical Research Institute of
Research
Infectious Diseases (USAMRIID) conducting preclinical research with
remdesivir and other Gilead-owned compounds. Two other agreements
between the Joint Project Management Office for Medical
Countermeasure Systems and Gilead funded the research performed by
USAMRIID. USAMRIID is continuing to conduct remdesivir research. The
most recent agreement, which took effect in 2020, was between the U.S.
Army Medical Materiel Development Activity and Gilead. DOD funding for
remdesivir research from 2014 through December 31, 2020, totaled $39.7
million.
Table 3: DOD Agreements and Funding for Remdesivir Research as of Dec. 31, 2020
Agreement type and DOD funding
research description Effective dates (in millions $) DOD component DOD partner(s)
Material transfer agreement W81XWH-14- 9/2014 – 9/2021 ─ USAMRIID Gilead Sciences
0380
Screening Gilead Sciences’ compound library
against representative viruses from multiple
virus families
Intramural research project 8/2015 – 9/2016 4.7 USAMRIID N/A
CB10291
Characterization of remdesivir efficacy
against filoviruses in nonhuman primate
disease models
Page 25 GAO-21-272 Biomedical Research
Appendix II: Federal Agreements and Funding
for Remdesivir Research
Agreement type and DOD funding
research description Effective dates (in millions $) DOD component DOD partner(s)
Technology investment agreement W911QY- 5/2016 – 10/2016 1.2 JPM–MCS Gilead Sciences
16-3-0001
A blinded, randomized evaluation of the
efficacy of 12-day dose-ranging regimens of
remdesivir against Ebola virus in rhesus
monkeys
Cooperative research and development 5/2016 – 5/2021 ─ USAMRIID Gilead Sciences
agreement and the Geneva
W81XWH-16-0297 Foundation
Generation of further confirmatory data
regarding the efficacy and safety of
remdesivir in treating nonhuman primates
infected with Ebola virus
“Other transaction” authority agreement for 8/2016 – ongoing 33.8a JPM–MCS Gilead Sciences
prototype
W911QY-16-9-0001
Preclinical development of remdesivir for the
treatment of Ebola virus and other filovirus
infections
Cooperative research and development 9/2016 – 9/2021 ─ USAMRIID Gilead Sciences
agreement and the Geneva
W81XWH-16-0472 Foundation
Five-year research program to complete the
preclinical development of remdesivir for
treatment of hemorrhagic fever viruses, such
as Ebola and Marburg viruses, through
various studies
Cooperative research and development 3/2020 – 3/2023 ─ USAMMDA Gilead Sciences
agreement
W81XWH-20-0110
lnvestigational use of remdesivir for the post-
exposure treatment of COVID-19 for DOD
personnel
Total 39.7
Legend: COVID-19 = Coronavirus Disease 2019, DOD = Department of Defense, USAMRIID = U.S. Army Research Institute of Infectious Diseases,
USAMMDA = U.S. Army Medical Materiel Development Activity, JPM-MCS = Joint Project Management Office for Medical Countermeasure Systems, ─
= no federal funding provided under the agreement
Source: GAO analysis of DOD documents and funding information. | GAO-21-272
a
Under the terms of this “other transaction” authority agreement signed in 2016, DOD would provide
about $50 million. According to DOD, the agency obligated $33.8 million of that amount as of Dec. 31,
2020.
NIH Agreements and NIH identified multiple agreements and intramural research projects
Funding for Remdesivir involving remdesivir (table 4). Intramural research was conducted at one
of NIH’s federal laboratories, the National Institute of Allergy and
Research
Infectious Diseases. NIH-funded university-based research and NIH’s
intramural research involving remdesivir is continuing. NIH funding for
Page 26 GAO-21-272 Biomedical Research
Appendix II: Federal Agreements and Funding
for Remdesivir Research
remdesivir research from 2014 through December 31, 2020, totaled $11.9
million.
Table 4: NIH Agreements and Funding for Remdesivir Research as of Dec. 31, 2020
Agreement type and research
project title Effective dates NIH funding Recipient of NIH funding
Contracts for preclinical research service
Preclinical research service contract 2018 $18,000 Utah State University
PC18VB9936
Evaluation of Remdesivir in Hamster Model
of Yellow Fever Virus
Preclinical research service contract 2019 $27,000 Utah State University
PC20VB13256
Efficacy of Remdesivir in Hamster Model of
Yellow Fever Virus
Preclinical research service contract 2020 $1,008 Utah State University
IV20RDB13570
Evaluation of Remdesivir for In Vitro Antiviral
Activity against SARS-CoV-2
Cooperative agreements
Cooperative agreement U19AI109680 2014-2020 $2,500,000 University of Alabama
Antiviral Drug Discovery and Development at Birminghama
Center – Coronavirus
Cooperative agreement U19AI142759 2019-2023 $400,000 University of Alabama
Antiviral Drug Discovery and Development at Birminghama
Center – Coronavirus
Cooperative agreement UM1AI068632 2020 $942,554 Johns Hopkins University
Pharmacokinetics and Safety of Remdesivir
for Treatment of COVID-19 in Pregnant
Women in the U.S.
Grants
Grant F31AI133952 2017-2019 $25,140 Vanderbilt University
Coronavirus Antiviral Nucleoside Analogs:
Inhibition and Reduced Susceptibility
Grant R01AI132178 2017-2021 $5,863,765 University of North Carolina at
Broad-Spectrum Antiviral GS-5734 to Treat Chapel Hill
MERS-CoV and Related Emerging CoV
Grant R21AI147057 2020 $155,000 University of California
Mechanistic Understanding and Inhibition of at Riverside
Zika NS5 Protein
Grant R00AI123498 2020-2021 $129,120 University of Wisconsin-Madison
Structural Studies of the Corona Virus Life
Cycle
Grant R01AI150246 2021b $447,930 University of Pennsylvania
Small Molecule Screening to Identify Novel
SARS-CoV-2 Therapeutics
Page 27 GAO-21-272 Biomedical Research
Appendix II: Federal Agreements and Funding
for Remdesivir Research
Grant R21AI159246 2021-2022b $442,002 University of Texas
GS-441524 Is Pharmacodynamically
Equivalent to Remdesivir and
Pharmacokinetically Superior Drug for the
Treatment of COVID-19
Intramural researchb
Research project AI001088-08 2016 $30,417 Laboratory of Virology, NIAID
Disease Modeling of Influenza and Other
Emerging Respiratory Viral Pathogens
Research project AI001088-09 2017 $38,374 Laboratory of Virology, NIAID
Disease Modeling of Influenza and Other
Emerging Respiratory Viral Pathogens
Research project AI001088-10 2018 $162,010 Laboratory of Virology, NIAID
Disease Modeling of Influenza and Other
Emerging Respiratory Viral Pathogens
Research project AI001088-11 2019 $238,496 Laboratory of Virology, NIAID
Disease Modeling of Influenza and Other
Emerging Respiratory Viral Pathogens
Research project AI001088-12 2020 $100,000 Laboratory of Virology, NIAID
Disease Modeling of Influenza and Other
Emerging Respiratory Viral Pathogens
Research project AI001259-01 2020 $330,000 Laboratory of Virology, NIAID
Emerging Respiratory Viruses –
Pathogenesis and Countermeasures
Research project EBOV-NHP-033E-9 2020 $12,333 NIAID Integrated Research
Evaluation of Zmapp vs. Remdesivir vs. the Facilityc
Combination
Total $11,863,149
Legend: COVID-19 = Coronavirus Disease 2019, NIAID = National Institute of Allergy and Infectious Diseases, NIH = National Institutes of Health
Source: GAO analysis of NIH documents and funding information. | GAO-21-272
a
University of Alabama at Birmingham is the lead university in a consortium of research teams from
several universities.
b
Funding for the agreement effective in 2021 was obligated before Dec. 31, 2020, according to NIH.
c
NIH identified three material transfer agreements with Gilead Sciences, which enabled NIAID to
obtain remdesivir for use in intramural research.
NIH also funded three clinical trials with remdesivir involving human
subjects (table 5). In these trials, remdesivir was tested for safety and
efficacy against Ebola virus disease and COVID-19. NIH funding for
clinical trials involving remdesivir from 2016 through December 31, 2020,
totaled $109.2 million.
Page 28 GAO-21-272 Biomedical Research
Appendix II: Federal Agreements and Funding
for Remdesivir Research
Table 5: NIH-funded Clinical Trials Involving Remdesivir as of Dec. 31, 2020
Clinical trial Effective period NIH funding (in millions)
Trial NCT 02818582 7/2016 –11/2017 $3.2
Partnership for Research on Ebola Virus in Liberia IV (PREVAIL IV)
Trial NCT 03719586 11/2018 – 8/2020 $17.4
Pamoja Tulinde Maisha (PALM [together save lives])
Trial NCT 04280705 2/2020 – ongoing $88.6
Adaptive COVID-19 Treatment Trial (ACTT)
Total $109.2
Legend: COVID-19 = Coronavirus Disease 2019, NIH = National Institutes of Health
Source: GAO analysis of NIH documents and funding information. | GAO-21-272
Page 29 GAO-21-272 Biomedical Research
Appendix III: Intellectual Property Provisions
Appendix III: Intellectual Property Provisions in
Federal Agency Agreements to Support
in Federal Agency Agreements to Support
Remdesivir Research
Remdesivir Research
Beginning in 2013, the Centers for Disease Control and Prevention
(CDC), Department of Defense (DOD), and National Institutes of Health
(NIH) entered into multiple agreements with Gilead Sciences, Inc.
(Gilead) and other entities to support remdesivir research. We analyzed
13 agreements between one of the agencies and Gilead. 1 Our analysis
shows that 12 of the 13 agreements included intellectual property
provisions recognizing that the agencies could patent inventions that
could result from their remdesivir research collaborations with Gilead
(table 6). Some of the agreements included government rights to subject
inventions, licenses, and data. 2 Of the 13 agreements, 12 contained
provisions recognizing that Gilead retained all rights to its existing
intellectual property. Five of the 13 agreements—all five were between
DOD and Gilead—listed specific patents and patent applications as
Gilead’s intellectual property.
Table 6: Government Intellectual Property Rights in Agreements with Gilead Sciences, 2013-2020
General IP Subject invention License Data
Agreement type Effective start date rights rights rights rights
CDC
Material transfer agreement 2/22/2013 X ─ ─ ─
NCEZID-V126727
Material transfer agreement 5/24/2016 X ─ ─ ─
D-389-16
Material transfer agreement 9/9/2020 ─ ─ ─ ─
D-541-20
DOD
Material transfer agreement 9/19/2014 X ─ ─ ─
W81XWH-14-0380
Technology investment 5/12/2016 X X X X
agreement
W911QY-16-3-0001a
Cooperative research and 5/13/2016 X X X X
development agreement
W81XWH-16-0297a
“Other transaction” authority 8/17/2016 X X X X
agreement for prototype
W911QY-16-9-0001a,b,c
1There were 11 other agreements between one of the agencies and a university.
2A subject invention is any invention conceived or first actually reduced to practice in the
performance of work under a funding agreement. Subject inventions can be made solely
or jointly by the parties of an agreement. The government’s rights to subject inventions
depend on the type and terms of the agreement.
Page 30 GAO-21-272 Biomedical Research
Appendix III: Intellectual Property Provisions in
Federal Agency Agreements to Support
Remdesivir Research
General IP Subject invention License Data
Agreement type Effective start date rights rights rights rights
Cooperative research and 9/16/2016 X X X X
development agreement
W81XWH-16-0472a,b
Cooperative research and 3/5/2020 X X X X
development agreement
W81XWH-20-0110a
NIH
Material transfer agreement 2/19/2016 X ─ ─ ─
2015-33642
Nonclinical evaluation 3/27/2018 X X X ─
agreement
2018-00023
Material transfer agreement 5/31/2019 X ─ ─ ─
2019-0287
Material transfer agreement 2/18/2020 X ─ ─ ─
2020-0108
Legend: IP = intellectual property, X = provision present in the agreement, ─ = provision absent in the agreement.
Source: GAO analysis of documents from the Centers for Disease Control and Prevention (CDC), Department of Defense (DOD), and National Institutes of Health (NIH). | GAO-21-272
Notes: General IP rights refer to provisions that recognize an agency’s existing IP rights or ability to
patent inventions. Subject invention rights refer to provisions that grant the government patent or
license rights to inventions made by an agency’s scientists, Gilead Sciences’ scientists, or both.
License rights refer to provisions that grant the government rights to a license to any of Gilead
Sciences’ existing patents or patentable inventions resulting from the research. Data rights refer to
provisions that grant the government rights to technical, scientific, or regulatory data.
a
Agreement between DOD and Gilead Sciences contains a section called “background intellectual
property” that lists remdesivir patents and patent applications, which are recognized as the
company’s intellectual property.
b
Agreement has an amendment that expands the background intellectual property owned by Gilead
Sciences.
c
Agreement stipulates that the agreement is not subject to the Bayh-Dole Act requirements.
Page 31 GAO-21-272 Biomedical Research
Appendix IV: Gilead Sciences’ Remdesivir Appendix IV: Gilead Sciences’ Remdesivir
Patents
Patents
GAO asked Gilead Sciences, Inc. (Gilead), the manufacturer of
remdesivir, to provide a list of U.S. remdesivir-related patents and patent
applications that was current as of December 31, 2020. Gilead provided
information for 16 patents (table 7), including one patent for using
remdesivir to treat animals. 1 Gilead listed eight of these patents on its
new drug application to the Food and Drug Administration (FDA) for
remdesivir under the brand name Veklury for treating COVID-19, which
FDA approved on October 22, 2020. 2
Table 7: Gilead Sciences’ U.S. Remdesivir Patents as of Dec. 31, 2020
Patent listed in
Patent claims Gilead Sciences’
remdesivir’s new drug
Priority date molecular application for
Patent number and title (issuance date)a Patent typeb structureb Vekluryc
8,008,264 4/23/2008 Compound X X
1’substituted carba-nucleoside analogs for (8/30/2011)
antiviral treatment
8,318,682 4/23/2008 Compound X X
1’substituted carba-nucleoside analogs for (11/27/2012)
antiviral treatment
RE46,762 4/23/2008 Compound X X
1’substituted carba-nucleoside analogs for (3/27/2018)
antiviral treatment
1Gilead also provided patent application numbers for eight nonprovisional applications
related to remdesivir: 14/926,063; 16/692,966; 16/852,102; 16/863,566; 16/865,209;
16/879,491; 16/881,419; and 17/069,248. The company informed us that it had also
submitted several provisional patent applications to the U.S. Patent and Trademark Office
(USPTO). An applicant can submit to USPTO a provisional patent application without a
formal patent claim to establish an early effective filing date. Applicants have 12 months to
file a nonprovisional patent application. All patent applications must be published after the
expiration of an 18-month period following the earliest effective filing date or priority date
claimed by an application. Following publication, the patent application is no longer
confidential. Patents generally expire 20 years after the nonprovisional patent application
is filed. For provisional applications, the confidentiality of patent applications, and general
patent terms, see 35 U.S.C. §§ 111(b), 122(a)-(b), 154(a), respectively.
2When seeking approval for marketing of a new drug in the United States, the company
submits a new drug application to FDA. See 21 U.S.C. § 355 and 21 C.F.R. § 314.50
(2019). The eight patents for Veklury are listed in FDA’s publication Approved Drug
Products with Therapeutic Equivalence Evaluations (commonly known as the Orange
Book), which identifies drug products approved on the basis of safety and effectiveness
under the Federal Food, Drug, and Cosmetic Act:
https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm, accessed Nov. 30, 2020.
Page 32 GAO-21-272 Biomedical Research
Appendix IV: Gilead Sciences’ Remdesivir
Patents
Patent listed in
Patent claims Gilead Sciences’
remdesivir’s new drug
Priority date molecular application for
Patent number and title (issuance date)a Patent typeb structureb Vekluryc
9,090,642 7/19/2010 Synthetic methods ─ ─
Methods for the preparation of (7/28/2015)
diasteromerically pure phosphoramidate
prodrugs
9,487,544 7/19/2010 Synthetic methods ─ ─
Methods for the preparation of (11/8/2016)
diasteromerically pure phosphoramidate
prodrugs
10,065,958 7/22/2010 Compound X X
Methods and compounds for treating (9/4/2018)
paramyxoviridae virus infections
10,696,679 7/22/2010 Method of use ─ ─
Methods and compounds for treating (6/30/2020)
paramyxoviridae virus infections
9,724,360 10/29/2014 Compound X X
Methods for treating filoviridae virus infections (8/8/2017)
9,949,994 10/29/2014 Compound X X
Methods for treating filoviridae virus infections (4/24/2018)
10,251,898 10/29/2014 Method of use ─ ─
Methods for treating filoviridae virus infections (4/9/2019)
10,695,357 10/29/2014 Method of use ─ ─
Methods for treating filoviridae virus infections (6/30/2020)
10,251,904 9/16/2015 Method of use ─ ─
Methods for treating arenaviridae and (4/9/2019)
coronaviridae virus infections
10,695,361 9/16/2015 Method of use ─ X
Methods for treating arenaviridae and (6/30/2020)
coronaviridae virus infections
10,682,368 3/14/2017 Method of use ─ ─
Methods for feline coronavirus infections (6/16/2020)
10,836,787 5/1/2017 Crystalline forms ─ ─
Crystalline forms of (S)-2-ethylbutyl 2-(((S)- (11/17/2020)
(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f]
[1,2,4]triazin-7-yl)-5-cyano-3,4-
dihydroxytetrahydrofuran-2-
yl)methoxy)(phenoxy)
phosphoryl)amino)propanoate
10,675,296 7/11/2017 Formulation ─ X
Compositions comprising an RNA polymerase (6/9/2020)
inhibitor and cyclodextrin for treating viral
infections
Source: GAO presentation of information from Gilead Sciences, the U.S. Patent and Trademark Office (USPTO), and Food and Drug Administration (FDA). | GAO-21-272
Notes: This table lists issued U.S. patents that Gilead Sciences identified as related to remdesivir.
Page 33 GAO-21-272 Biomedical Research
Appendix IV: Gilead Sciences’ Remdesivir
Patents
a
Priority date is the date the initial patent application is filed. Issuance date is the date when USPTO
grants the patent and the patent becomes enforceable, which means that the patent owner can
prevent others from making, selling, or using the claimed invention. Patents generally expire 20 years
after the initial nonprovisional patent application is filed.
b
The content of this column is based on information provided by Gilead Sciences.
c
These patents are listed in FDA’s publication Approved Drug Products with Therapeutic Equivalence
Evaluations (commonly known as the Orange Book) for Veklury, Gilead Sciences’ brand name for
remdesivir. The Orange Book identifies drug products approved on the basis of safety and
effectiveness under the Federal Food, Drug, and Cosmetic Act:
https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm, accessed Nov. 30, 2020.
Page 34 GAO-21-272 Biomedical Research
Appendix V: GAO Contact and Staff
Appendix V: GAO Contact and Staff
Acknowledgements
Acknowledgements
Candice N. Wright at (202) 512-6888 or WrightC@gao.gov.
GAO Contact
In addition to the contact named above, the following individuals made
Staff contributions to this report: Robert J. Marek (Assistant Director), Sada
Acknowledgements Aksartova (Analyst-in-Charge), Adam J. Brooks, John E. Dicken, Robert
Copeland, Eric Charles, Hayden Huang, Rebecca Parkhurst, Patrick
Harner, Serena Lo, Louise Fickel, Anika McMillon, and Cheron J. Brooks.
(104433)
Page 35 GAO-21-272 Biomedical Research
The Government Accountability Office, the audit, evaluation, and investigative
GAO’s Mission arm of Congress, exists to support Congress in meeting its constitutional
responsibilities and to help improve the performance and accountability of the
federal government for the American people. GAO examines the use of public
funds; evaluates federal programs and policies; and provides analyses,
recommendations, and other assistance to help Congress make informed
oversight, policy, and funding decisions. GAO’s commitment to good government
is reflected in its core values of accountability, integrity, and reliability.
The fastest and easiest way to obtain copies of GAO documents at no cost is
Obtaining Copies of through our website. Each weekday afternoon, GAO posts on its website newly
GAO Reports and released reports, testimony, and correspondence. You can also subscribe to
GAO’s email updates to receive notification of newly posted products.
Testimony
Order by Phone The price of each GAO publication reflects GAO’s actual cost of production and
distribution and depends on the number of pages in the publication and whether
the publication is printed in color or black and white. Pricing and ordering
information is posted on GAO’s website, https://www.gao.gov/ordering.htm.
Place orders by calling (202) 512-6000, toll free (866) 801-7077, or
TDD (202) 512-2537.
Orders may be paid for using American Express, Discover Card, MasterCard,
Visa, check, or money order. Call for additional information.
Connect with GAO on Facebook, Flickr, Twitter, and YouTube.
Connect with GAO Subscribe to our RSS Feeds or Email Updates. Listen to our Podcasts.
Visit GAO on the web at https://www.gao.gov.
Contact FraudNet:
To Report Fraud,
Website: https://www.gao.gov/fraudnet/fraudnet.htm
Waste, and Abuse in
Automated answering system: (800) 424-5454 or (202) 512-7700
Federal Programs
Orice Williams Brown, Managing Director, WilliamsO@gao.gov, (202) 512-4400,
Congressional U.S. Government Accountability Office, 441 G Street NW, Room 7125,
Relations Washington, DC 20548
Chuck Young, Managing Director, youngc1@gao.gov, (202) 512-4800
Public Affairs U.S. Government Accountability Office, 441 G Street NW, Room 7149
Washington, DC 20548
Stephen J. Sanford, Acting Managing Director, spel@gao.gov, (202) 512-4707
Strategic Planning and U.S. Government Accountability Office, 441 G Street NW, Room 7814,
External Liaison Washington, DC 20548
Please Print on Recycled Paper.
File and source
- File
- gao-21-272.pdf
- Size
- 1,252,114 bytes
- SHA-256
- 30a060f50f11c24ac7ec73bf778cc3aa32d63a384be98882e0a5d1b2e733f46b
- Our copy
- gao-21-272.pdf
- Original
- www.gao.gov